177 related articles for article (PubMed ID: 37142185)
21. Histopathological changes in morphea and their clinical correlates: Results from the Morphea in Adults and Children Cohort V.
Walker D; Susa JS; Currimbhoy S; Jacobe H
J Am Acad Dermatol; 2017 Jun; 76(6):1124-1130. PubMed ID: 28285783
[TBL] [Abstract][Full Text] [Related]
22. Esophageal abnormalities in juvenile localized scleroderma: is it associated with other extracutaneous manifestations?
Valões CCM; Novak GV; Brunelli JB; Kozu KT; Toma RK; Silva CA
Rev Bras Reumatol Engl Ed; 2017; 57(6):521-525. PubMed ID: 29173689
[TBL] [Abstract][Full Text] [Related]
23. Localized scleroderma: a series of 52 patients.
Toledano C; Rabhi S; Kettaneh A; Fabre B; Fardet L; Tiev KP; Cabane J
Eur J Intern Med; 2009 May; 20(3):331-6. PubMed ID: 19393504
[TBL] [Abstract][Full Text] [Related]
24. Skin mapping for the classification of generalized morphea.
Teske N; Welser J; Jacobe H
J Am Acad Dermatol; 2018 Feb; 78(2):351-357. PubMed ID: 29332706
[TBL] [Abstract][Full Text] [Related]
25. Overview of Juvenile localized scleroderma and its management.
Li SC; Zheng RJ
World J Pediatr; 2020 Feb; 16(1):5-18. PubMed ID: 31786801
[TBL] [Abstract][Full Text] [Related]
26. Juvenile Localized Scleroderma: Updates and Differences from Adult-Onset Disease.
Vasquez-Canizares N; Li SC
Rheum Dis Clin North Am; 2021 Nov; 47(4):737-755. PubMed ID: 34635302
[TBL] [Abstract][Full Text] [Related]
27. Response evaluation of musculoskeletal involvement in patients with deep morphea treated with methotrexate and prednisolone: a combined MRI and clinical approach.
Schanz S; Henes J; Ulmer A; Kötter I; Fierlbeck G; Claussen CD; Horger M
AJR Am J Roentgenol; 2013 Apr; 200(4):W376-82. PubMed ID: 23521481
[TBL] [Abstract][Full Text] [Related]
28. Ocular involvement in children with localised scleroderma: a multi-centre study.
Zannin ME; Martini G; Athreya BH; Russo R; Higgins G; Vittadello F; Alpigiani MG; Alessio M; Paradisi M; Woo P; Zulian F;
Br J Ophthalmol; 2007 Oct; 91(10):1311-4. PubMed ID: 17475707
[TBL] [Abstract][Full Text] [Related]
29. A retrospective study on clinical subtypes and management of morphea in 10 Italian Dermatological Units.
Virdi A; Patrizi A; Cambiaghi S; Diociaiuti A; El Hachem M; Schena D; Bassi A; Bonamonte D; Brazzelli V; Belloni Fortina A; Pepe P; DI Lernia V; Neri I
Ital J Dermatol Venerol; 2021 Aug; 156(4):446-454. PubMed ID: 33070566
[TBL] [Abstract][Full Text] [Related]
30. Pediatric morphea (localized scleroderma): review of 136 patients.
Christen-Zaech S; Hakim MD; Afsar FS; Paller AS
J Am Acad Dermatol; 2008 Sep; 59(3):385-96. PubMed ID: 18571769
[TBL] [Abstract][Full Text] [Related]
31. Presenting characteristics and progression of pediatric-onset morphea: Interim analysis of a prospective registry.
Ng AT; Brandling-Bennett HA; Drolet BA; Siegel DH; Chiu YE
Pediatr Dermatol; 2023; 40(4):606-609. PubMed ID: 37317938
[TBL] [Abstract][Full Text] [Related]
32. Patients with morphea with neurologic involvement: A cross-sectional study and review from the morphea in adults and children cohort.
Abbas LF; Joseph AK; Zhu JL; Okuda D; Jacobe HT
J Am Acad Dermatol; 2023 Jan; 88(1):172-174. PubMed ID: 34998956
[No Abstract] [Full Text] [Related]
33. Interventions for morphea.
Albuquerque JV; Andriolo BN; Vasconcellos MR; Civile VT; Lyddiatt A; Trevisani VF
Cochrane Database Syst Rev; 2019 Jul; 7(7):CD005027. PubMed ID: 31309547
[TBL] [Abstract][Full Text] [Related]
34. Disabling pansclerotic morphea of childhood with extracutaneous manifestations.
Kura MM; Jindal SR
Indian J Dermatol; 2013 Mar; 58(2):159. PubMed ID: 23716826
[TBL] [Abstract][Full Text] [Related]
35. Exploring the impact of paediatric localized scleroderma on health-related quality of life: focus groups with youth and caregivers.
Zigler CK; Ardalan K; Hernandez A; Caliendo AE; Magee KE; Terry MA; Mann CM; Torok KS
Br J Dermatol; 2020 Oct; 183(4):692-701. PubMed ID: 31955419
[TBL] [Abstract][Full Text] [Related]
36. Patterns of joint involvement in juvenile idiopathic arthritis and prediction of disease course: A prospective study with multilayer non-negative matrix factorization.
Eng SWM; Aeschlimann FA; van Veenendaal M; Berard RA; Rosenberg AM; Morris Q; Yeung RSM;
PLoS Med; 2019 Feb; 16(2):e1002750. PubMed ID: 30807586
[TBL] [Abstract][Full Text] [Related]
37. Changes in Disease Activity and Damage Over Time in Patients With Morphea.
O'Brien JC; Nymeyer H; Green A; Jacobe HT
JAMA Dermatol; 2020 May; 156(5):513-520. PubMed ID: 32236501
[TBL] [Abstract][Full Text] [Related]
38. Association between quality of life and clinical characteristics in patients with morphea.
Bali G; Kárpáti S; Sárdy M; Brodszky V; Hidvégi B; Rencz F
Qual Life Res; 2018 Oct; 27(10):2525-2532. PubMed ID: 29922914
[TBL] [Abstract][Full Text] [Related]
39. Prospective study to evaluate the clinical and radiological outcome of patients with scleroderma of the face.
Careta MF; Leite Cda C; Cresta F; Albino J; Tsunami M; Romiti R
Autoimmun Rev; 2013 Sep; 12(11):1064-9. PubMed ID: 23791631
[TBL] [Abstract][Full Text] [Related]
40. Diagnosis and management of morphea and lichen sclerosus and atrophicus in children.
Pope E; Laxer RM
Pediatr Clin North Am; 2014 Apr; 61(2):309-19. PubMed ID: 24636648
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
